These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 14567090)
21. [Diagnosis of thrombophilia based on coagulation and genetic studies]. Bałszan-Kowalska I Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477 [TBL] [Abstract][Full Text] [Related]
22. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population. Torres JD; Cardona H; Alvarez L; Cardona-Maya W; Castañeda SA; Quintero-Rivera F; Cadavid A; Bedoya G; Tobón L Am J Hematol; 2006 Dec; 81(12):933-7. PubMed ID: 16917913 [TBL] [Abstract][Full Text] [Related]
23. Resistance to activated protein C--frequent etiologic factor for venous thrombosis. Simkova M; Simko F; Kovacs L Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376 [TBL] [Abstract][Full Text] [Related]
24. Detection of factor V Leiden in Thai patients with venous thrombosis. Prayoonwiwat W; Arnutti P; Hiyoshi M; Nathalang O; Suwanasophon C; Kokaseam R; Krutvecho T; Tatsumi N Asian Pac J Allergy Immunol; 2000 Jun; 18(2):105-8. PubMed ID: 10928623 [TBL] [Abstract][Full Text] [Related]
25. The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox. Hirmerova J; Seidlerova J; Subrt I QJM; 2014 Sep; 107(9):715-20. PubMed ID: 24633260 [TBL] [Abstract][Full Text] [Related]
26. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856 [TBL] [Abstract][Full Text] [Related]
27. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778 [TBL] [Abstract][Full Text] [Related]
28. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Nojima J; Kuratsune H; Suehisa E; Kawasaki T; Machii T; Kitani T; Iwatani Y; Kanakura Y Thromb Haemost; 2002 Nov; 88(5):716-22. PubMed ID: 12428083 [TBL] [Abstract][Full Text] [Related]
29. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. Egesel T; Büyükasik Y; Dündar SV; Gürgey A; Kirazli S; Bayraktar Y J Clin Gastroenterol; 2000 Jan; 30(1):66-71. PubMed ID: 10636214 [TBL] [Abstract][Full Text] [Related]
30. Activated protein C resistance and factor V Leiden: a review. Rosendorff A; Dorfman DM Arch Pathol Lab Med; 2007 Jun; 131(6):866-71. PubMed ID: 17550313 [TBL] [Abstract][Full Text] [Related]
31. Coexistence of hypofibrinogenemia and factor V Leiden mutation: is the balance shifted to thrombosis? Miljić P; Nedeljkov-Jančić R; Zuvela M; Subota V; Dorđević V Blood Coagul Fibrinolysis; 2014 Sep; 25(6):628-30. PubMed ID: 24637696 [TBL] [Abstract][Full Text] [Related]
32. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. Legnani C; Cini M; Cosmi B; Mattarozzi S; Lo Manto G; Palareti G Thromb Haemost; 2004 Apr; 91(4):712-8. PubMed ID: 15045132 [TBL] [Abstract][Full Text] [Related]
33. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075 [TBL] [Abstract][Full Text] [Related]
34. Factor V Leiden with deep venous thrombosis. Gardner J Clin Lab Sci; 2003; 16(1):6-9. PubMed ID: 12587652 [TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Sundquist K; Wang X; Svensson PJ; Sundquist J; Hedelius A; Larsson Lönn S; Zöller B; Memon AA Thromb Haemost; 2015 Nov; 114(6):1156-64. PubMed ID: 26245493 [TBL] [Abstract][Full Text] [Related]
36. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798 [TBL] [Abstract][Full Text] [Related]
37. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Castaman G; Tosetto A; Ruggeri M; Rodeghiero F Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192 [TBL] [Abstract][Full Text] [Related]
38. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency. Yap S; O'Donnell KA; O'Neill C; Mayne PD; Thornton P; Naughten E Thromb Haemost; 1999 Apr; 81(4):502-5. PubMed ID: 10235428 [TBL] [Abstract][Full Text] [Related]
39. Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Omarova F; Uitte de Willige S; Simioni P; Ariëns RA; Bertina RM; Rosing J; Castoldi E Blood; 2014 Aug; 124(9):1531-8. PubMed ID: 24951429 [TBL] [Abstract][Full Text] [Related]
40. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG; Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]